AB0722 TREATMENT RESPONSE TO METHOTREXATE MONOTHERAPY IN ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS: DATA FROM THE NOR-DMARD STUDY

Background: Juvenile idiopathic arthritis (JIA) can cause considerable pain and disability in childhood adulthood. The number of studies exploring the efficacy medications adult JIA patients is limited. Methotrexate (MTX) a commonly used medication for this patient group. Objectives: To explore effects MTX monotherapy (mono) on disease activity diagnosed with JIA, compared to weighted rheumatoid (RA) cohort. Methods: Data from NOR-DMARD, longitudinal observational study enrolling > 18 years starting or switching DMARD treatment inflammatory joint disease, was [1]. Patients mono treatment, clinical diagnosis other arthropathies before age 16 years, were identified population. RA same regimen included comparative purposes. Disease measurements remission rates collected at baseline, 3 6 months. Changes absolute after months calculated. Remission change baseline between cohort weights based gender, using linear logistic regression continuous categorical variables, respectively. Results: 2201 analyses, 101 (80.2% female, mean (SD) 35.6 (13.0) duration 24.8 (12.9) years), 2100 (69.4% 56.6 (13.6) 4.1 (8.1) years) analyses. Age, gender distribution differed significantly cohorts. Both group improved across all measures (Table 1). groups had progressive increase 1, Figure greater improvement ESR months, SJC28 TJC28, DAS28, SDAI MHAQ There no significant differences rates. Table 1. Baseline Change JIA* RA* Diff. § ESR, mm/h 20.4 (18.2) 28.7 (22.2) 3.7 (-0.6 8.1) -3.1 (15.8) -9.6 (18.7) -5.7 (-10.1 -1.4) -3.0 (17.5) -11.3 (19.8) -5.4 (-10.8 0.03) 3.9 (4.8) 6.9 (5.7) 2.0 (0.9 3.2) -1.8 (3.3) -3.5 (5.5) -0.9 (-1.9 0.02) -4.2 (5.6) -1.5 (-2.6 -0.5) TJC 28 4.5 (4.9) 8.0 (7.1) 3.1 (1.9 4.2) -0.8 (4.2) (7.4) -1.9 (-3.1 -0.7) -1.4 (3.8) -4.0 (6.8) -2.3 (-3.4 -1.1) DAS28 4.0 (1.3) 4.9 0.6 (0.2 0.9) -0.6 (1.2) -1.2 (1.5) -0.5 (-0.9 -0.2) -0.7 (-1.0 18.3 (11.3) 26.0 5.6 (2.7 8.4) -6.0 (9.7) -11.0 (14.0) (-5.9 -6.3 (8.2) -12.8 (14.2) -5.1 (-7.8 -2.2) PGA 51.0 (24.6) 48.3 (24.3) -4.5 (-10.0 1.1) -13.2 (25.3) -14.7 (26.5) -1.0 (-7.4 5.3) (23.8) -14.3 (26.7) -4.6 (-11.9 2.7) 0.5 (0.5) 0.7 0.1 (-0.05 0.2) -0.2 (0.3) -0.1 (-0.2 -0.0) -0.16 (-0.3 -0.1) *Mean Weighted difference, coefficient (95 % confidence interval) Mean 3- 6-month error bars (SE) Conclusion: Adult presented initiation mono. magnitude smaller than group, but obtained similar as patients. References: [1]Kvien, T.K., et al., A Norwegian register: prescriptions DMARDs biological agents rheumatic diseases. Clin Exp Rheumatol, 2005. 23 (5 Suppl 39): p. S188-94. Disclosure Interests: Imane Bardan: None declared, Karen Minde Fagerli: Joe Sexton: Gunnstein Bakland Speakers bureau: Abbvie, Consultant of: UCB, Pfizer, Novartis, Pawel Mielnik: Liz Marina Paucar Loli: Tore K. Kvien Amgen, Celltrion, Egis, Evapharma, Ewopharma, Hikma, Oktal, Sandoz Sanofi, AbbVie, Biogen, Eli Lilly, Gilead, Mylan, Grant/research support from: BMS, MSD, Pfizer Eirik kristianslund: Anna-Birgitte Aga Dr. reports personal fees Novartis outside submitted work